Insmed (NASDAQ:INSM) Price Target Raised to $110.00
Insmed (NASDAQ:INSM – Free Report) had its price objective increased by UBS Group from $105.00 to $110.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts have also weighed in on INSM. Wells Fargo & […]
Insmed (NASDAQ:INSM – Free Report) had its price objective increased by UBS Group from $105.00 to $110.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts have also weighed in on INSM. Wells Fargo & […]
